Donald Zurbay - 17 Sep 2024 Form 4 Insider Report for Silk Road Medical Inc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 Sep 2024
Net transaction value: -$3,638,740
SEC form: 4
Accepted by SEC: 18 Sep 2024, 21:12:36 UTC
Prior SEC filing: 16 Jul 2024
Next SEC filing: 09 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Mhairi Jones, by power of attorney

Key filing fact

Donald Zurbay filed Form 4 for Silk Road Medical Inc on 18 Sep 2024.

Key facts

This page summarizes Donald Zurbay's Form 4 filing for Silk Road Medical Inc.
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Sep 2024, 21:12.

Change

Previous filing in this sequence was filed on 16 Jul 2024.
Current net transaction value: -$3,638,740.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SILK transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -12,610
Change %: -100%
Price
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SILK transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $3,123,603
Shares: -146,031
Change %: -100%
Price: $21.39
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 146,031
Exercise price: $6.11
Footnotes: F4

SILK transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $448,312
Shares: -29,206
Change %: -100%
Price: $15.35
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,206
Exercise price: $12.15
Footnotes: F5

SILK transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $66,825
Shares: -8,910
Change %: -100%
Price: $7.50
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,910
Exercise price: $20.00
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Donald Zurbay is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

Footnote F2

Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

Footnote F3

Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

Footnote F4

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Footnote F5

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Footnote F6

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.